These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2054450)

  • 1. Negative symptoms in schizophrenia and nailfold plexus visibility.
    Poole JH; Maricq HR; Alson E; Willerman L
    Biol Psychiatry; 1991 Apr; 29(8):757-73. PubMed ID: 2054450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A family study of nailfold plexus visibility in psychotic disorders.
    Clementz BA; Iacono WG; Ficken J; Beiser M
    Biol Psychiatry; 1992 Feb; 31(4):378-90. PubMed ID: 1558900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated nailfold plexus visibility aggregates in families and is associated with a specific negative symptom pattern in schizophrenia.
    Vuchetich JP; Liska JL; Dionisio DP; Stanwyck JJ; McGuire KA; Sponheim SR
    Psychiatry Res; 2008 Jul; 160(1):30-7. PubMed ID: 18514327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficit schizophrenia does not co-aggregate with high nailfold plexus visibility.
    Vuchetich JP; Miranowski SK; Leitten WL; Hill SM; Kirkpatrick B
    Schizophr Res; 2010 Oct; 123(1):88-9. PubMed ID: 19942408
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between nailfold plexus visibility and clinical, neuropsychological, and brain structural measures in schizophrenia.
    Curtis CE; Iacono WG; Beiser M
    Biol Psychiatry; 1999 Jul; 46(1):102-9. PubMed ID: 10394479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visibility of the nailfold plexus and heredity.
    Maricq HR; Jones MB
    Biol Psychiatry; 1976 Apr; 11(2):205-15. PubMed ID: 971446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study.
    Kendler KS; McGuire M; Gruenberg AM; Walsh D
    Am J Psychiatry; 1995 May; 152(5):755-64. PubMed ID: 7726316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative symptoms of schizophrenia and plexus visibility: a replication with medicated and unmedicated patients.
    Poole JH; Maricq HR; Willerman L
    Biol Psychiatry; 1993 Sep; 34(6):414-6. PubMed ID: 8105980
    [No Abstract]   [Full Text] [Related]  

  • 9. Does familiality predispose to both emergence and persistence of psychosis? A follow-up study.
    Verdoux H; van Os J; Sham P; Jones P; Gilvarry K; Murray R
    Br J Psychiatry; 1996 May; 168(5):620-6. PubMed ID: 8733802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive and negative symptoms in families with schizophrenia.
    Bassett AS; Collins EJ; Nuttall SE; Honer WG
    Schizophr Res; 1993 Dec; 11(1):9-19. PubMed ID: 8297809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nailfold capillary plexus visibility in relation to schizotypy.
    Gooding DC; Miller MD
    Schizophr Res; 1998 Aug; 32(3):207-12. PubMed ID: 9720126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia, gender, and affect.
    Seeman MV
    Can J Psychiatry; 1996 Jun; 41(5):263-4. PubMed ID: 8793143
    [No Abstract]   [Full Text] [Related]  

  • 14. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Insight in schizophrenia: assessment of 31 patients with different scales].
    Travers D; Levoyer D; Millet B
    Encephale; 2008 Jan; 34(1):66-72. PubMed ID: 18514153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The deficit syndrome in schizophrenic and nonschizophrenic patients: preliminary studies.
    Gerbaldo H; Philipp M
    Psychopathology; 1995; 28(1):55-63. PubMed ID: 7871122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing positive and negative symptoms in children and adolescents.
    Fields JH; Grochowski S; Lindenmayer JP; Kay SR; Grosz D; Hyman RB; Alexander G
    Am J Psychiatry; 1994 Feb; 151(2):249-53. PubMed ID: 8296898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new rating scale for negative symptoms: the Motor-Affective-Social Scale.
    Trémeau F; Goggin M; Antonius D; Czobor P; Hill V; Citrome L
    Psychiatry Res; 2008 Sep; 160(3):346-55. PubMed ID: 18722021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twin concordance for DSM-III-R schizophrenia.
    Onstad S; Skre I; Torgersen S; Kringlen E
    Acta Psychiatr Scand; 1991 May; 83(5):395-401. PubMed ID: 1853734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resemblance of psychotic symptoms and syndromes in affected sibling pairs from the Irish Study of High-Density Schizophrenia Families: evidence for possible etiologic heterogeneity.
    Kendler KS; Karkowski-Shuman L; O'Neill FA; Straub RE; MacLean CJ; Walsh D
    Am J Psychiatry; 1997 Feb; 154(2):191-8. PubMed ID: 9016267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.